GenBioPro

GenBioPro is an innovative pharmaceutical company dedicated to providing accessible reproductive healthcare. One of their notable products is the first FDA-approved generic mifepristone in the US. This groundbreaking medication has expanded access to medical abortion by offering stabilized product supply, improved packaging, and timely fulfillment.

GenBioPro aims to put reproductive health care within reach for all individuals, regardless of income, gender, race, or location. As of January 3, 2023, the US Food & Drug Administration has approved changes to the Risk Evaluation and Mitigation Strategy (REMS) program for generic mifepristone tablets, 200 mg. These changes help improve access to medical abortion care by removing the requirement for in-person dispensing, allowing telemedicine care in states that permit it, as well as enabling mail and in-person dispensing from certified pharmacies.

The Prescriber Agreement has also been streamlined for convenience. GenBioPro offers a Certified Prescriber Agreement for healthcare providers who wish to prescribe generic mifepristone. This agreement is portable, allowing prescribers to use it wherever they practice.

Additionally, they have a Certified Pharmacy Agreement for pharmacies that want to dispense generic mifepristone. Certified pharmacies benefit from stable product supply and pharmacy-friendly packaging. GenBioPro is committed to breaking down barriers and supporting the community of providers, pharmacies, patients, and advocates working to ensure universal access to reproductive health care.

They believe that everyone has the right to reproductive health care, including access to medical abortion. Learn more about GenBioPro and their mission to deliver affordable and effective products for individuals seeking abortion care